Irbesartan
- Generic Name
- Irbesartan
- Brand Names
- Avalide, Avapro, Ifirmacombi, Karvea, Karvezide, Irbesartan Teva, Ifirmasta (previously Irbesartan Krka), Irbesartan Zentiva (previously Irbesartan Winthrop), Aprovel
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N6O
- CAS Number
- 138402-11-6
- Unique Ingredient Identifier
- J0E2756Z7N
- Background
Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected to be well controlled on monotherapy. Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry co...
- Indication
Irbesartan is indicated to treat hypertension and diabetic nephropathy in hypertensive patients with type 2 diabetes, elevated serum creatinine, and proteinuria. A combination product with hydrochlorothiazide is indicated for hypertension in patients with uncontrolled hypertension with monotherapy or first line in patients not expected to be well controlled ...
- Associated Conditions
- Diabetic Nephropathy, Hypertension
- Associated Therapies
- -
Role of AT1-receptor Blockers in Insulin-induced Vasodilation.
- Conditions
- Interventions
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2011-03-17
- Lead Sponsor
- Maastricht University Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00742066
- Locations
- 🇳🇱
University Hospital Maastricht, Maastricht, P.O. Box 5800, Netherlands
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00660309
- Locations
- 🇺🇸
Novartis Investigator Site, Boston, Massachusetts, United States
Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 151
- Registration Number
- NCT00657059
- Locations
- 🇨🇳
The 1st Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, China
A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2011-09-16
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 261
- Registration Number
- NCT00635232
- Locations
- 🇺🇸
MD Medical Research, Oxon Hill, Maryland, United States
🇺🇸East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Cedar Crosse Research Center, Chicago, Illinois, United States
Irbesartan and Adhesion Molecules in AF
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- University of Magdeburg
- Target Recruit Count
- 60
- Registration Number
- NCT00613496
- Locations
- 🇩🇪
University Hospital Magdeburg; Div. of Cardiology, Magdeburg, Germany
Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice
- First Posted Date
- 2007-11-27
- Last Posted Date
- 2007-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 115
- Registration Number
- NCT00564187
- Locations
- 🇹🇳
Sanofi-Aventis, Megrine, Tunisia
The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
- Conditions
- First Posted Date
- 2007-11-22
- Last Posted Date
- 2007-11-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1005
- Registration Number
- NCT00562809
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Randomized, Parallel, Comparison, Double-Blind Efficacy & Safety Study of APROVEL Versus Placebo in Chinese Patients With Hypertensive Type II Diabetic Patients With Microalbuminuria
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2007-11-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 241
- Registration Number
- NCT00561964
Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol
- Conditions
- First Posted Date
- 2007-10-25
- Last Posted Date
- 2007-10-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 44
- Registration Number
- NCT00549133
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Nephropathy In Type 2 Diabetes and Cardio-renal Events
- First Posted Date
- 2007-09-27
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 850
- Registration Number
- NCT00535925
- Locations
- 🇮🇹
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy, Naples, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.